GE HealthCare Technologies Inc. (GEHC)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $37.54B
Last updated: Nov 17, 2026 at 11:06 AM ET
GE HealthCare Technologies Inc. (GEHC) Earnings: Report Dates and Results
GE HealthCare Technologies (GEHC) is expected to report earnings on Feb 8, 2027. In the quarter ended Sep 30, 2026, GE HealthCare Technologies reported EPS of $1.34, above the $1.21 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GEHC has an expected report date of Feb 8, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 10.4% above the $1.44 reported for the quarter ended Dec 31, 2025.
GEHC Earnings Call
The latest GEHC earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 16 quarters below that had an estimate, GEHC beat 14 and missed 2. Revenue for the quarter ended Sep 30, 2026 was $5.51B, up 7.2% from $5.14B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.34 | $1.21 | $1.16 - $1.25 | +10.74% | Beat | +25.2% | 18 | 1 up, 0 down | Oct 28, 2026 | $5.51B |
| Jun 30, 2026 | $1.13 | $1.04 | $1.01 - $1.07 | +8.65% | Beat | +6.6% | 14 | 0 up, 14 down | Jul 29, 2026 | $5.29B |
| Mar 31, 2026 | $0.99 | $1.05 | $0.96 - $1.07 | -5.71% | Miss | -2.0% | 15 | 2 up, 1 down | Apr 29, 2026 | $5.13B |
| Dec 31, 2025 | $1.44 | $1.40 | $1.20 - $1.46 | +2.86% | Beat | -8.3% | 16 | 1 up, 0 down | Feb 4, 2026 | $5.70B |
| Sep 30, 2025 | $1.07 | $1.05 | $0.94 - $1.11 | +1.90% | Beat | -6.1% | 15 | 1 up, 1 down | Oct 29, 2025 | $5.14B |
| Jun 30, 2025 | $1.06 | $0.92 | $0.85 - $0.96 | +15.22% | Beat | +6.0% | 15 | 1 up, 0 down | Jul 30, 2025 | $5.01B |
| Mar 31, 2025 | $1.01 | $0.91 | $0.90 - $0.93 | +10.99% | Beat | +12.2% | 13 | 1 up, 1 down | Apr 30, 2025 | $4.78B |
| Dec 31, 2024 | $1.57 | $1.26 | $1.22 - $1.30 | +24.60% | Beat | +33.1% | 14 | 1 up, 0 down | Feb 13, 2025 | $5.32B |
| Sep 30, 2024 | $1.14 | $1.05 | $1.00 - $1.10 | +8.57% | Beat | +15.2% | 14 | 2 up, 1 down | Oct 30, 2024 | $4.86B |
| Jun 30, 2024 | $1.00 | $0.98 | $0.93 - $1.02 | +2.04% | Beat | +8.7% | 12 | 2 up, 0 down | Jul 31, 2024 | $4.84B |
| Mar 31, 2024 | $0.90 | $0.91 | $0.87 - $0.96 | -1.10% | Miss | +5.9% | 11 | 1 up, 0 down | Apr 30, 2024 | $4.65B |
| Dec 31, 2023 | $1.18 | $1.07 | $1.04 - $1.09 | +10.28% | Beat | -2.5% | 11 | 0 up, 0 down | Feb 6, 2024 | $5.21B |
| Sep 30, 2023 | $0.99 | $0.90 | $0.87 - $0.92 | +10.00% | Beat | -10.8% | 10 | 0 up, 0 down | Oct 31, 2023 | $4.82B |
| Jun 30, 2023 | $0.92 | $0.87 | $0.81 - $0.93 | +5.75% | Beat | -51.6% | 7 | 0 up, 0 down | Jul 25, 2023 | $4.82B |
| Mar 31, 2023 | $0.85 | $0.79 | $0.77 - $0.81 | +7.59% | Beat | N/A | 4 | 0 up, 0 down | Apr 25, 2023 | $4.71B |
| Dec 31, 2022 | $1.21 | $1.06 | N/A | +14.15% | Beat | N/A | N/A | N/A | Jan 30, 2023 | $4.94B |
| Sep 30, 2022 | $1.11 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 8, 2022 | $4.58B |
| Jun 30, 2022 | $1.90 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 13, 2022 | $4.48B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $4.58, within 4 cents of the year before. It was $4.22 for the year ended Dec 31, 2022, the oldest of the 4 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $4.58 | N/A |
| Dec 31, 2024 | $4.61 | +17.0% |
| Dec 31, 2023 | $3.94 | -6.6% |
| Dec 31, 2022 | $4.22 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,000 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,023 | 14 | |
| 2026Q2 | Jun 30, 2026 | 8,788 | 12 | |
| 2026Q1 | Mar 31, 2026 | 7,369 | 13 | |
| 2025Q4 | Dec 31, 2025 | 2,034 | 5 | |
| 2025Q3 | Sep 30, 2025 | 8,317 | 13 | |
| 2025Q2 | Jun 30, 2025 | 8,591 | 11 | |
| 2025Q1 | Mar 31, 2025 | 8,224 | 12 | |
| 2024Q4 | Dec 31, 2024 | 8,392 | 12 |
2026Q3 Earnings Call
Opening remarks
Carolynne Borders Head of Investor Relations Thanks, operator. Good morning, and welcome to GE Healthcare's Third Quarter 2026 Earnings Call. I am joined by our President and CEO, Peter J. Arduini; CFO, William K. Grogan; and Controller and Chief Accounting Officer, George Andrew Newcomb. Our conference call remarks will include both GAAP and non-GAAP financial results. Reconciliations between GAAP and non-GAAP measures can be found in today's press release and in the presentation slides available on our website. During this call, we will make forward-looking statements about our performance. These statements are based on how we see things today. As described in our SEC filings, actual results may differ materially due to risks and uncertainties. With that, I will hand the call over to Peter.
Peter J. Arduini President and CEO Thanks, Carolynne. Good morning, and thank you for joining us today. Before I review highlights from the quarter, I want to take a moment to welcome Bill. He brings tremendous experience and a strong track record, and I am looking forward to partnering with him as we execute against our strategy and deliver on our priorities. Looking at our third quarter results on slide 3, we delivered strong top-line growth and margin expansion across all segments. Broad-based demand in advanced imaging solutions and pharmaceutical diagnostics supported healthy orders, book-to-bill, and backlog. Heartbeat is strengthening how we run the company and helping our teams deliver on commercial and operational simplification. A great example of performance driven by Heartbeat this quarter is Patient Care Solutions. The team identified root causes of prior supply challenges and implemented standard work and daily management to drive ongoing improvements. This drove backlog conversion and stronger operational performance. Taken together, momentum in our business has enabled us to raise our full-year 2026 guidance, which Bill will cover later in the call. Turning to slide 4, let's look at how we are advancing our growth strategy. We reached key regulatory milestones in the quarter on two imaging platforms with market-differentiating features. We received CE marking for Photonova Spectra, our photon-counting CT system, and Starguide GX, our SPECT/CT system, is pending FDA clearance. This broadens our ability to commercialize in more markets. We also expanded our ultrasound platforms in cardiovascular, women's health, and general imaging, with the launch of several new products to meet the growing demand for noninvasive imaging. We continue to see general imaging ultrasound as an attractive market where we are investing for the long term. With growing demand, staffing constraints, and more distributed care, ultrasound's versatility across a broad range of exams is increasingly valuable. PDx delivered another excellent quarter with growth in contrast media and radiopharmaceuticals, including proprietary tracers aligned to disease states.
Frequently Asked Questions About GEHC
When is GE HealthCare Technologies's next earnings date?
GE HealthCare Technologies's next earnings report is expected for Feb 8, 2027.
Did GEHC beat earnings estimates last quarter?
Yes. GE HealthCare Technologies reported EPS of $1.34 for the quarter ended Sep 30, 2026, above the $1.21 estimate, a 10.74% surprise.
What EPS do analysts expect from GEHC next quarter?
The consensus EPS estimate for GE HealthCare Technologies for the quarter ending Dec 31, 2026 is $1.59 from 21 analysts, with estimates from $1.50 to $1.68.
How often does GEHC beat earnings estimates?
GE HealthCare Technologies beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +8.66%.
GEHC pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors